Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Phase 3

Terminated

• Conditions: Mild Cognitive Impairment; Alzheimer's Disease; Dementia
• Interventions: Drug: Flutemetamol (Vizamyl)

• Registration Number: NCT02353949
• Lead Sponsor: University of Zurich

Brief Summary

The study examines subjects where there might be an indication for Amyloid-PET according to the Criteria defined by the Amyloid Imaging Task Force. In these subjects the impact of a Flutemetamol (Vizamyl)-Positron-Emission-Tomography -Scan (PET) on clinical management and disease course will be studied over 6 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-01-22
• Study First Submitted QC: 2015-01-28
• Study First Posted: 2015-02-03
• Study Start: 2015-05
• Primary Completion: 2019-12-10
• Study Completion: 2019-12-10
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-16
• Last Update Posted: 2020-01-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Dementia expert considers an Amyloid-scan appropriate according to Amyloid-imaging task force criteria (AIT) after conference with an Amyloid-PET expert

• Preambles of the AIT-Criteria are fulfilled

  1. A cognitive complaint with objectively confirmed impairment
  2. AD as a possible diagnosis, but when the diagnosis is uncertain after a comprehensive evaluation by a dementia expert
  3. When knowledge of the presence or absence of Abeta pathology is expected to increase diagnostic certainty and alter Management
  <!-- -->
  1. Patients with persistent or progressive unexplained MCI
  2. Patients satisfying core clinical criteria for possible AD because of unclear clinical presentation, either an atypical clinical course or an etiologically mixed presentation
  3. Patients with progressive dementia and atypically early age of onset (65 years or less in age)
  4. other situations where preambles of AIT-Criteria are fulfilled

• Diagnosis was established in a memory clinic or by an experienced physician in dementia diagnostics

• The diagnostic procedures comprise in minimum MRI, neuropsychology, routine blood test for exclusion of symptomatic causes

• MMSE >15

• Competency to consent

• Trial partner willing to support study physician

• Written informed consent by both patient and trial partner

• Understanding of German language

• Treating physician willing to collaborate with the study team

Read More

Exclusion Criteria

• Cognitive impairment which can be attributed to another underlying medical condition that renders a possibility of Alzheimer's disease very unlikely (thus violating preamble B)

• Clinically significant Depression (decided upon clinical assessment)

• MRI exclusion criteria

• PET exclusion criteria

  1. Allergy to Flutemetamol or any of the excipients of the solution for injections
  2. History of severe allergic reactions to drugs or allergens
  3. Pregnancy or lactation

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Flutmetamol Group	Flutemetamol (Vizamyl)	PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose

Primary Outcome Measures

Name	Time	Method
Change of ADAS-cog 11 score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.	Three months after initiation of standard treatment

Secondary Outcome Measures

Name	Time	Method
Change of ADCS-ADL score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.	Three months after initiation of standard treatment
Change of ADCS-CGIC score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.	Three months after initiation of standard treatment
Change of MMSE score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.	Three months after initiation of standard treatment

Trial Locations

Locations (1)

University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy; 🇨🇭 Schlieren, Zurich, Switzerland